Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK1 | Q96PY6 | 7/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 5/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | MAP2 | P11137 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20568345 | 0.83 | NEK1 (0.39) | NEK1GPR35MAP2 | |
| SCHEMBL30794689 | 0.81 | KDM4E (0.53) | GPR35MAP2KMT2AKDM4EMEN1 | |
| SCHEMBL20569867 | 0.77 | GPR35 (0.39) | NEK1GPR35SCN9A | |
| SCHEMBL20569212 | 0.76 | NEK1 (0.32) | NEK1GPR35 | |
| SCHEMBL23327755 | 0.75 | GPR35 (0.54) | GPR35MAP2KMT2AKDM4EMEN1 | |
| SCHEMBL23327820 | 0.75 | NEK1 (0.32) | NEK1GPR35 | |
| SCHEMBL20568180 | 0.74 | GPR35 (0.50) | NEK1GPR35SCN9A | |
| SCHEMBL20568482 | 0.74 | BRAF (0.36) | GPR35MAP2KMT2AKDM4EMEN1 | |
| SCHEMBL20568485 | 0.72 | NEK1 (0.38) | NEK1KDM4E | |
| SCHEMBL20568609 | 0.69 | KEAP1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210137886-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-05-13 | — | — | US | claimed |
| US-20210137886-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| US-20210137886-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210137886-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | MGAM, GAA, LCT | NEK1 3363/4885GPR35 4727/4885PTGDR2 3660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.